ArticleStroke2020
Risks of Stroke and Mortality in Atrial Fibrillation Patients Treated With Rivaroxaban and Warfarin.
Article in Stroke, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 50 citations in OpenAlex.
- Early anti-coagulation therapy in new-onset atrial fibrillation after coronary artery bypass grafting: a randomized trial pilot study.BMC cardiovascular disorders · 2024Trial
- Article
- Interpretable machine learning models for stroke risk prediction in patients with newly diagnosed atrial fibrillation.NPJ digital medicine · 2026Article
- Collagen-targeted tracers for molecular imaging of atrial fibrosis and sensitive detection of atrial fibrillation.NPJ cardiovascular health · 2025Article
- Clinical Perspectives on Stroke Prevention in Patients with Non-valvular Atrial Fibrillation in the Philippines.Cureus · 2025Review
- A worsened prognosis for patients after stroke with newly diagnosed atrial fibrillation compared to having a preexisting arrhythmia.Archives of medical science : AMS · 2025Article
- In-hospital mortality and its associated factors among hospitalized stroke patients at public hospitals of Eastern Ethiopia.BMC cardiovascular disorders · 2024Article
- Liposomal Bupivacaine Analgesia in Deep Inferior Epigastric Perforator Flap Breast Reconstruction: A Retrospective Cohort Study.Plastic and reconstructive surgery. Global open · 2024Article
- Article
- Review
- Review
- Trends in surgical ablation at the time of cardiac surgery among patients with atrial fibrillation.JTCVS open · 2023Article
- Long-Term Outcomes after Stroke in Patients with Atrial Fibrillation: A Single Center Study.International journal of environmental research and public health · 2023Article
- Antiplatelet treatment patterns and outcomes of secondary stroke prevention in the United States.Heliyon · 2023Article
- Selection of Non-vitamin K Antagonist Oral Anticoagulant for Stroke Prevention in Atrial Fibrillation Based on Patient Profile: Perspectives from Vietnamese Experts. Part 1.European cardiology · 2023Review
- Predicting short-term outcomes in atrial-fibrillation-related stroke using machine learning.Frontiers in neurology · 2023Article
- Article
- Comparative Effectiveness and Safety of Direct Oral Anticoagulants Versus Warfarin Among Adults With Cancer and Atrial Fibrillation.Circulation. Cardiovascular quality and outcomes · 2022Article
- Risk Levels and Adverse Clinical Outcomes Among Patients With Nonvalvular Atrial Fibrillation Receiving Oral Anticoagulants.JAMA network open · 2022Article
- A Comparative Study of the Clinical Benefits of Rivaroxaban and Warfarin in Patients With Non-valvular Atrial Fibrillation With High Bleeding Risk.Frontiers in cardiovascular medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Purpose- Oral anticoagulation therapy is standard of care for patients with nonvalvular atrial fibrillation to prevent stroke. This study compared rivaroxaban and warfarin for stroke and all-cause mortality risk reduction in a real-world setting. Methods- This retrospective cohort study (2011-2017) included de-identified patients from the Optum Clinformatics Database who started treatment with rivaroxaban or warfarin within 30 days following initial diagnosis of nonvalvular atrial fibrillation. Before nonvalvular atrial fibrillation diagnosis, patients had 6 months of continuous health plan enrollment and CHA
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.